Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MTOR | P42345 | 19/20 | 1.00 |
| ▸ | PIK3CA | P42336 | 4/20 | 1.00 |
| ▸ | KCNH2 | Q12809 | 3/20 | 1.00 |
| ▸ | RICTOR | Q6R327 | 2/20 | 1.00 |
| ▸ | RPTOR | Q8N122 | 2/20 | 1.00 |
| ▸ | MAPKAP1 | Q9BPZ7 | 2/20 | 1.00 |
| ▸ | MLST8 | Q9BVC4 | 2/20 | 1.00 |
| ▸ | PIK3CD | O00329 | 1/20 | 1.00 |
| ▸ | FECH | P22830 | 1/20 | 0.67 |
| ▸ | PIK3R1 | P27986 | 1/20 | 0.67 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Ku-0063794 SCHEMBL29454796 | 1.00 | MTOR (1.00) | MTORPIK3CAKCNH2RICTORRPTOR | |
| Ku-0063794 SCHEMBL29350060 | 1.00 | MTOR (1.00) | MTORPIK3CAKCNH2RICTORRPTOR | |
| Ku-0063794 SCHEMBL290208 | 1.00 | MTOR (1.00) | MTORPIK3CAKCNH2RICTORRPTOR | |
| SCHEMBL2926233 | 0.97 | MTOR (0.94) | MTORPIK3CAKCNH2RICTORRPTOR | |
| SCHEMBL14239586 | 0.93 | MTOR (0.86) | MTORPIK3CAKCNH2RICTORRPTOR | |
| SCHEMBL10092312 | 0.92 | MTOR (0.86) | MTORPIK3CAKCNH2RICTORRPTOR | |
| SCHEMBL4748699 | 0.92 | MTOR (0.85) | MTORPIK3CAKCNH2RICTORRPTOR | |
| SCHEMBL22787101 | 0.91 | MTOR (0.84) | MTORPIK3CAKCNH2RICTORRPTOR | |
| SCHEMBL2900826 | 0.91 | MTOR (0.83) | MTORPIK3CAKCNH2RICTORRPTOR | |
| SCHEMBL14089019 | 0.91 | MTOR (0.83) | MTORPIK3CAKCNH2RICTORRPTOR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 190 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4554581-A1 | COMBINATION THERAPY COMPRISING GSPT1-DIRECTED MOLECULAR GLUE DEGRADERS AND PI3K/AKT/MTOR PATHWAY INHIBITORS | Monte Rosa Therapeutics AG (CH) | 2025-05-21 | — | — | EP | claimed |
| WO-2024015855-A1 | COMBINATION THERAPY COMPRISING GSPT1-DIRECTED MOLECULAR GLUE DEGRADERS AND PI3K/AKT/mTOR PATHWAY INHIBITORS | MONTE ROSA THERAPEUTICS, INC. (US) | 2024-01-18 | — | — | WO | claimed |
| US-20220249504-A1 | LONGEVITY SIGNATURES AND THEIR APPLICATIONS | THE BRIGHAM AND WOMEN'S HOSPITAL, INC. | 2022-08-11 | — | — | US | claimed |
| US-20210379021-A1 | METHOD FOR PREPARING AND DELIVERING BISANTRENE FORMULATIONS | RACE ONCOLOGY LTD (AU) | 2021-12-09 | — | — | US | claimed |
| EP-3860575-A1 | METHOD FOR PREPARING AND DELIVERING BISANTRENE FORMULATIONS | Race Oncology Ltd. (AU) | 2021-08-11 | — | — | EP | claimed |
| WO-2020072948-A1 | METHOD FOR PREPARING AND DELIVERING BISANTRENE FORMULATIONS | RACE ONCOLOGY LTD. (AU) | 2020-04-09 | — | — | WO | claimed |
| US-20140315943-A1 | COMBINATION THERAPY OF HSP90 INHIBITORY COMPOUNDS WITH MTOR/P13K INHIBITORS | SYNTA PHARMACEUTICALS CORP. (US) | 2014-10-23 | — | — | US | claimed |
| WO-2012162372-A1 | COMBINATION THERAPY OF HSP90 INHIBITORY COMPOUNDS WITH MTOR/P13K INHIBITORS | SYNTA PHARMACEUTICALS CORP. (US) | 2012-11-29 | — | — | WO | claimed |
| EP-4729121-A2 | NOVEL COMPOSITIONS AND METHODS FOR TREATING OR PREVENTING DERMAL DISORDERS | Drexel University (US) | 2026-04-22 | — | — | EP | disclosed |
| US-20260097028-A1 | Methods of Treating Myeloproliferative Neoplasms | KARTOS THERAPEUTICS INC (US) | 2026-04-09 | — | — | US | disclosed |
| US-20250387383-A1 | METHODS OF TREATING MYELOPROLIFERATIVE NEOPLASMS | KARTOS THERAPEUTICS, INC. (US) | 2025-12-25 | — | — | US | disclosed |
| EP-3352755-B1 | TOPICAL COMPOSITION COMPRISING RAPAMYCIN FOR USE IN TREATING OR PREVENTING SEBORRHEIC KERATOSIS OR ACTINIC KERATOSIS | UNIV DREXEL (US) | 2025-12-24 | — | — | EP | disclosed |
| US-12502414-B2 | Second generation Seneca Valley virus oncolytic therapy: compositions and methods thereof | SENECA THERAPEUTICS, INC. (US) | 2025-12-23 | — | — | US | disclosed |
| US-20250340615-A1 | NOVEL FUSION MOLECULES AND USES THEREOF | FOUNDATION MEDICINE, INC. (US) | 2025-11-06 | — | — | US | disclosed |
| US-7902189-B2 | antitumor agent, anticarcinogenic agents; 7-Chloro-2-((2S,6R)-2,6-dimethyl-morpholin-4-yl)-4-morpholin-4-yl-pyrido[2,3-d]pyrimidine; inhibitors of mTOR kinase | ASTRAZENECA AB (SE) | 2011-03-08 | — | — | US | disclosed |
| US-7902189-B2 | antitumor agent, anticarcinogenic agents; 7-Chloro-2-((2S,6R)-2,6-dimethyl-morpholin-4-yl)-4-morpholin-4-yl-pyrido[2,3-d]pyrimidine; inhibitors of mTOR kinase | ASTRAZENECA AB (SE) | 2011-03-08 | — | — | US | disclosed |
| WO-2010129622-A1 | MTOR PATHWAY INHIBITORS FOR TREATING OCULAR DISORDERS | MACUSIGHT, INC. (US) | 2010-11-11 | — | — | WO | disclosed |
| US-20080081809-A1 | Novel Compounds | KUDOS PHARMACEUTICALS LIMITED (GB) | 2008-04-03 | — | — | US | disclosed |
| US-20080081809-A1 | Novel Compounds | KUDOS PHARMACEUTICALS LIMITED (GB) | 2008-04-03 | — | — | US | disclosed |
| WO-2007060404-A1 | PYRIDO-,PYRAZO- AND PYRIMIDO-PYRIMIDINE DERIVATIVES AS mTOR INHIBITORS | KUDOS PHARMACEUTICALS LIMITED (GB) | 2007-05-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250387383-A1 | METHODS OF TREATING MYELOPROLIFERATIVE NEOPLASMS | JAK2, JAK1, MPL | MTOR 11/4885PIK3CA 20/4885KCNH2 4326/4885 |
| US-20140315943-A1 | COMBINATION THERAPY OF HSP90 INHIBITORY COMPOUNDS WITH MTOR/P13K INHIBITORS | MTOR, HSP90AB1, HSP90AA1 | MTOR 1/4885PIK3CA 18/4885KCNH2 4732/4885 |
| US-20260097028-A1 | Methods of Treating Myeloproliferative Neoplasms | JAK2, TP53, CDKN1A | MTOR 15/4885PIK3CA 52/4885KCNH2 4400/4885 |
| US-20250340615-A1 | NOVEL FUSION MOLECULES AND USES THEREOF | RPS27A, CD2BP2, FGB | MTOR 4823/4885PIK3CA 2528/4885KCNH2 4714/4885 |
| US-20210379021-A1 | METHOD FOR PREPARING AND DELIVERING BISANTRENE FORMULATIONS | CYP3A43, CYP1A1, UGT1A3 | MTOR 4582/4885PIK3CA 2400/4885KCNH2 2740/4885 |
| US-20220249504-A1 | LONGEVITY SIGNATURES AND THEIR APPLICATIONS | GLA, LIMS1, GLB1 | MTOR 1479/4885PIK3CA 2961/4885KCNH2 4843/4885 |
| US-20080081809-A1 | Novel Compounds | SLC10A1, ABCB11, PKD1 | MTOR 203/4885PIK3CA 1845/4885KCNH2 3954/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.